NICE has recommended Merck and AstraZeneca’s PARP inhibitor Lynparza as a maintenance treatment for relapsed platinum-sensitive ovarian, fallopian tube, or peritoneal cancer patients in England whose cancers harbor BRCA1 or BRCA2 mutations and who have received two prior courses of Pt-based CT
The recommendation was based on the results from the P-III trial (SOLO-2) & showed that Lynparza can significantly delay disease progression and improved OS in BRCA1/2-mutated ovarian cancer patients
Lynparza was approved in the US & EU for the treatment of advanced ovarian cancer patients with BRCA1/2 mutations after 1L CT in 2018 & 2019, respectively
Ref: Pharmiweb | Image: Merck
Related News:- AstraZeneca Reports P-III Trial (DUO-E) Results of Imfinzi (durvalumab) + Lynparza (olaparib) for Advanced Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
